CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $67K, compared with -$804K a year earlier. Trailing-twelve-month accounts payables was $1.09M. Over 3 fiscal years it compounded at +48.1% a year.

Context

  • Accounts payables amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $67K or moves back toward the trailing-twelve-month quarterly average of $273K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67K-89.8% QoQ
Last fiscal yearDec 2025
$221K+174.4% YoY
LTMMar 2026
$1.09M+164.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+108.3%——
1 year+174.4%——
3-year CAGR+48.1%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
221K USD
Year-over-year change
+174.4%

Accounts Payables vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 accounts payables of $1.09M is the 9th largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +164.9% is the 4th highest of 9, against a peer median of -26.9%.
  • Accounts payables amounts to 3.1% of revenue for CTMX, versus a peer median of 5.8%.
CTMX Competitors Peer median
Accounts Payables for CTMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$45.36M +357.1%—17.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$13.63M -5.5%+52.3%12167.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$10.3M -925.0%—13.0%
XNCRXencor, Inc.LTM Jun 2026$6.13M -229.5%+0.3%5.8%
STROSutro Biopharma, Inc.LTM Mar 2026$3.13M -534.1%+26.3%3.1%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M -48.2%-70.5%1.5%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.14M +288.2%—15.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.09M +164.9%+48.1%3.1%
ADAGAdagene Inc.LTM Jun 2024$0 ——0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) $0-26.9%+13.3%5.8%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.61M)(99.32M)(569K)31.87M(17.37M)
Depreciation & Amortization2.71M5.86M2.18M1.77M1.38M
Deferred Income Tax272K0000
Stock-Based Compensation13.17M13.13M8.56M7.67M6.3M
Change in Working Capital(54.7M)(30.65M)(62.51M)(126.42M)(68.58M)
Accounts Receivables8K(35.2M)32.55M329K1.09M
Inventory11.64M0000
Accounts Payables(139K)68K(1.43M)(297K)221K
Other Working Capital(66.21M)4.47M(93.64M)(126.45M)(69.89M)
Other Non-Cash Items3.13M13.33M(3.69M)(1.12M)2.68M
Operating Cash Flow(119.03M)(110.79M)(56.04M)(86.23M)(75.59M)
Capital Expenditures(1.61M)(1.74M)(840K)(310K)(220K)
Acquisitions (Net)(24.1M)0000
Purchases of Investments(99.9M)0(424.83M)(155.49M)(192.52M)
Sales of Investments124M100M275M255.5M133M
Other Investing Activities24.1M0000
Investing Cash Flow22.49M98.26M(150.67M)99.7M(59.74M)
Debt Repayment00000
Common Stock Issued107.71M648K30.23M6.91M110.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.5M00613K0
Financing Cash Flow110.21M648K30.23M7.52M110.45M
Effect of Forex Changes00000
Net Change in Cash13.67M(11.88M)(176.48M)20.99M(24.89M)
Free Cash Flow(120.64M)(112.53M)(56.88M)(86.54M)(75.81M)

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.